Aglaia Oncology Funds
Overview
Aglaia Oncology Funds is a Dutch venture capital firm that invests in early-stage oncology drug development companies.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Sapreme Technologies BV | Oct 2021 | Series A | Lead |
| ORCA Therapeutics | Sep 2024 | VC Round | Co-investor |
| InteRNA Technologies | Feb 2021 | Series B Extension | Co-investor |
| MIMETAS | Apr 2018 | Series B | Co-investor |
For institutional investors. Book with your work email.
Key People
Karl Rothweiler
Founder, Founding Investor, Member Of The Supervisory Board
Eric van der Putten
Partner
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Aglaia Oncology Funds based?
Aglaia Oncology Funds is headquartered in Netherlands.
When was Aglaia Oncology Funds founded?
Aglaia Oncology Funds was founded in 2004.
How many portfolio companies does Aglaia Oncology Funds have?
Aglaia Oncology Funds has 7 portfolio companies in Caplight's dataset.
What are some companies in Aglaia Oncology Funds's portfolio?
Portfolio companies visible on Caplight include Sapreme Technologies BV, ORCA Therapeutics, InteRNA Technologies, MIMETAS.
What was Aglaia Oncology Funds's most recent investment shown here?
Aglaia Oncology Funds's most recent investment in this portfolio sample was in ORCA Therapeutics in 2024.
What sectors does Aglaia Oncology Funds focus on?
Aglaia Oncology Funds focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Aglaia Oncology Funds focus on?
Aglaia Oncology Funds typically invests at the MultiStage stage.